证券代码：301196 证券简称：唯科科技 公告编号：2024-038 近日公司已完成上述工商变更登记及章程的备案手续，并取得了厦门市湖里 区市场监督管理局换发的《营业执照》，现将相关情况公告如下： 一、新营业执照基本信息 名称：宇科塑料（厦门）有限公司 统一社会信用代码：91350200612028784Y 类型：有限责任公司(自然人投资或控股的法人独资) 厦门唯科模塑科技股份有限公司 关于完成收购宇科塑料（厦门）有限公司 100%股权工商变更登记并 取得营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2023 年 11 月 15 日召开第二届董事会第七次会议，审议通过了《关于收购宇科塑料（厦门）有限 公司 100%股权的议案》，具体内容详见公司于 2023 年 11 月 16 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于收购宇科塑料（厦门）有限公司 100% 股权的公告》。 法定代表人：王燕 成立日期：1995 年 7 月 11 日 住所：厦门市湖里区马 ...

证券代码：301196 证券简称：唯科科技 公告编号：2024-039 厦门唯科模塑科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 1 月 27 日 召开第二届董事会第九次会议、第二届监事会第八次会议，审议通过《关于回购 股份方案的议案》，同意公司使用自有资金不低于人民币 5,000 万元（含）且不 超过人民币 1 亿元（含）以集中竞价交易方式回购公司股份用于实施股权激励或 员工持股计划，回购价格不超过人民币 45 元/股（含），回购期限自公司董事会 审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至 上月末的回购进展情况。现将公司截至 2024 年 5 月 31 日回购股份的进展情况公 告如下： （一）公司首次回购股份的 ...

证券代码：301196 证券简称：唯科科技 公告编号：2024-037 厦门唯科模塑科技股份有限公司 关于使用部分闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 4 月 21 日召开第二届董事会第十次会议及 2024 年 5 月 14 日召开 2023 年度股东大会， 审议通过了《关于使用部分闲置自有资金进行现金管理的议案》，同意公司使用 不超过人民币 15 亿元（含）的闲置自有资金进行现金管理，用于购买安全性高、 流动性好的金融产品或结构性存款等理财产品，使用期限为自公司股东大会审议 通过之日起不超过 12 个月（含）。在上述额度及决议有效期内，可循环滚动使 用。具体内容详见公司 2024 年 4 月 23 日刊登于巨潮资讯网（www.cninfo.com.cn） 上的《关于使用部分闲置自有资金进行现金管理的公告》。现将近期使用部分闲 置自有资金进行现金管理的情况公告如下： 一、新增现金管理的基本情况 自 2024 年 3 月 20 日至本公告日，公司（含子 ...

通过"全景路演"（http://rs.p5w.net）投资者关系互动平台参与公 参与单位名称 司 2023 年年报业绩说明会暨投资者网上集体接待日活动的社会公众、 及人员姓名 投资者 证券代码：301196 证券简称：唯科科技 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 编号：2024-002 | --- | --- | --- | --- | |------------|-------|----------------|--------------| | | □ | 特定对象调研 □ | 分析师会议 | | | □ | 媒体采访 | 业绩说明会 | | 投资者关系 | □ | 新闻发布会 | □ 路演活动 | | 活动类别 | □ | 现场参观 | | | | □ | 其他（ ） | | | --- | --- | |-------------------------|----------------------------------------------------------------------------------------------------------------- ...

证券代码：301196 证券简称：唯科科技 公告编号：2024-036 厦门唯科模塑科技股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会存在否决议案的情形，被否决的议案为《关于拟续聘会计师事务 所的议案》。鉴于拟续聘的大华会计师事务所（特殊普通合伙）近日受到中国证券监督 管理委员会江苏监管局行政处罚，基于审慎性原则，该议案未获得股东表决通过。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 3、根据法律、法规、规章和规范性文件对上市公司回购股份事宜的相关规定，上市 公司回购专用账户中的股份不享有股东大会表决权，截至本次股东大会股权登记日，公 司总股本 124,800,000 股，公司回购专用证券账户持有股份 1,409,275 股，故公司本次 股东大会有表决权股份总数为 123,390,725 股。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： （1）现场会议时间：2024 年 5 月 14 日（星期二）下午 2:00 （2）网络投票时间：2024 年 5 月 ...

国浩律师（上海）事务所 股东大会法律意见书 国浩律师（上海）事务所 关于厦门唯科模塑科技股份有限公司 2023 年年度股东大会的法律意见书 致：厦门唯科模塑科技股份有限公司 厦门唯科模塑科技股份有限公司（以下简称"公司"）2023 年年度股东大会 （以下或称"本次股东大会"）于 2024 年 5 月 14 日召开，国浩律师（上海）事务 所（以下简称"本所"）接受公司的委托，指派律师（以下简称"本所律师"）出 席会议，并依据《中华人民共和国证券法》《中华人民共和国公司法》、中国证券 监督管理委员会《上市公司股东大会规则》和《厦门唯科模塑科技股份有限公司章 程》（以下简称"《公司章程》"）出具本法律意见书。 本所律师已经按照有关法律、行政法规及规范性文件的规定对公司本次股东大 会召集、召开程序是否合法以及是否符合《公司章程》规定、出席会议人员的资格、 召集人资格的合法有效性和股东大会表决程序、表决结果的合法有效性发表法律意 见。法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的 法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、行政法规及规范性文件 ...

证券代码：301196 证券简称：唯科科技 公告编号：2024-035 厦门唯科模塑科技股份有限公司 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日 在巨潮资讯网（http://www.cninfo.com.cn）刊登了《关于召开 2023 年度股东 大会的通知》，公司现就召开 2023 年度股东大会的有关事项作如下提示： 一、召开股东大会的基本情况 1、会议届次：2023 年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：公司第二届董事会第十次会议审议通过了《关 于召开 2023 年度股东大会的议案》，本次股东大会会议的召开符合《公司法》 《证券法》《上市公司股东大会规则》等相关法律、行政法规、规范性文件及《公 司章程》等有关规定。 4、会议召开的时间： （1）现场会议时间：2024 年 5 月 14 日（星期二）下午 2:00 （1）现场投票：股东本人出席现场会议或者通过授权委托书委托他人出席 现场会议； （ ...

证券代码：301196 证券简称：唯科科技 公告编号：2024-033 厦门唯科模塑科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 1 月 27 日 召开第二届董事会第九次会议、第二届监事会第八次会议，审议通过《关于回购 股份方案的议案》，同意公司使用自有资金不低于人民币 5,000 万元（含）且不 超过人民币 1 亿元（含）以集中竞价交易方式回购公司股份用于实施股权激励或 员工持股计划，回购价格不超过人民币 45 元/股（含），回购期限自公司董事会 审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至 上月末的回购进展情况。现将公司截至 2024 年 4 月 30 日回购股份的进展情况公 告如下： 一、回购股份的进展情况 ...

Dividend Distribution - The company plans to distribute a cash dividend of 9 RMB per 10 shares (including tax) to all shareholders, based on a total of 124,800,000 shares[3]. - The company has a total of 124,800,000 shares for the dividend distribution, with no bonus shares being issued[3]. - The company plans to distribute a cash dividend of RMB 9 per 10 shares, totaling RMB 112,320,000, which accounts for 100% of the total profit distribution[172]. - The profit distribution plan is based on a total share capital of 124,800,000 shares, with no stock bonus or capital reserve conversion[172]. Financial Performance - The company's operating revenue for 2023 reached ¥1,341,074,347.86, representing a 39.97% increase compared to ¥958,097,728.84 in 2022[17]. - The net profit attributable to shareholders for 2023 was ¥168,069,329.73, a slight increase of 2.83% from ¥163,450,635.39 in 2022[17]. - The net profit after deducting non-recurring gains and losses decreased by 6.22% to ¥116,155,426.61 in 2023 from ¥123,865,236.36 in 2022[17]. - The net cash flow from operating activities for 2023 was ¥156,936,759.28, down 25.94% from ¥211,918,489.55 in 2022[17]. - The total assets at the end of 2023 amounted to ¥3,695,914,140.16, reflecting a 9.26% increase from ¥3,382,654,238.20 at the end of 2022[17]. - The net assets attributable to shareholders increased by 4.04% to ¥3,082,975,745.74 at the end of 2023 from ¥2,963,241,086.51 at the end of 2022[17]. - The basic earnings per share for 2023 was ¥1.3467, up 2.83% from ¥1.3097 in 2022[17]. - The total operating revenue for 2023 reached ¥1,341,074,347.86, representing a year-on-year increase of 39.97% compared to ¥958,097,728.84 in 2022[62]. - The revenue from the mold and injection molding industry was ¥948,146,727.59, accounting for 70.70% of total revenue, with a year-on-year growth of 30.30%[62]. - The health appliance sector saw a significant revenue increase of 77.43%, totaling ¥376,514,383.89, up from ¥212,207,856.33 in the previous year[62]. - Domestic sales accounted for 59.46% of total revenue, amounting to ¥797,355,796.27, which is an 83.32% increase from the previous year[62]. Market and Product Development - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25]. - The company operates in the "C29 Rubber and Plastic Products Industry," specifically in "C2929 Manufacturing of Plastic Parts and Other Products," supported by national policies promoting high-end manufacturing[26]. - The precision injection molding and injection parts are widely used in electronics, automotive, home appliances, and new energy sectors, with the company establishing a global production base across multiple countries including Germany, Malaysia, Mexico, and Vietnam[27]. - The plastic products industry in China is expected to maintain a steady long-term growth trend, with increasing applications in automotive materials due to stricter emission regulations[28]. - The health product market, including air purifiers, is rapidly growing, driven by rising consumer health awareness and environmental concerns, leading to increased sales of disinfecting air purifiers[29]. - The company has developed a "mold-integration" business model, expanding from precision injection molds to injection parts and health products, providing a one-stop solution for various industries[30]. - The company’s health products include air purifiers, humidifiers, and glass cleaning machines, catering to the growing demand for home health solutions[43]. - The company is developing new energy-efficient food processing products to expand its product line and market presence[74]. - The company is focusing on optimizing its air purification product designs to enhance market competitiveness[74]. - The company aims to expand its product system by integrating health products into its existing offerings, enhancing collaboration with clients and creating new profit growth points[117]. Research and Development - The company has maintained a high level of R&D investment, establishing provincial and national-level technology centers to foster innovation and improve production conditions[52]. - The company has accumulated a total of 462 authorized patents, including 23 invention patents, which support its long-term competitive advantage in precision injection mold design and processing technologies[52]. - The company expanded its R&D personnel to 331 in 2023, a 15.73% increase from 286 in 2022[75]. - The proportion of R&D personnel to total employees decreased to 12.76% in 2023 from 15.65% in 2022[75]. - The company is investing 30 million RMB in R&D for new technologies aimed at enhancing product efficiency[148]. - The company plans to enhance its product development by focusing on "large, precise, and complex" manufacturing technologies, aiming to shorten innovation cycles and improve R&D quality[115]. Operational Efficiency - The company has maintained a stable financial position despite fluctuations in net profit and cash flow, indicating resilience in its operations[25]. - The company’s production lines for precision injection molds, injection parts, and health products create synergistic effects, enhancing overall operational efficiency[44]. - The company employs an "order-based production" model for injection parts, aligning production plans with sales orders and inventory levels[48]. - The company has established a rapid response mechanism to enhance customer service and has set up a professional after-sales service team[60]. - The company has developed an information management system that integrates resources across procurement, production, sales, and R&D, improving operational efficiency[60]. - The overall gross margin has slightly decreased compared to the previous year due to rising labor costs and market competition, prompting the company to enhance product quality and operational efficiency[122]. Strategic Investments and Acquisitions - The company is considering strategic acquisitions to enhance its market position, with a budget of 100 million RMB allocated for potential deals[148]. - The company plans to acquire 100% equity of Yuke Plastic (Xiamen) Co., Ltd[156]. - The company is expanding its market presence through strategic investments and acquisitions[156]. - The company has made significant equity investments totaling CNY 116,400,000.00 during the reporting period, including CNY 57,900,000.00 in Xiamen Teck Mould Industrial Co., Ltd. and CNY 58,500,000.00 in Wanxin (Xiamen) New Materials Co., Ltd.[89]. Governance and Compliance - The company held 4 shareholder meetings during the reporting period, ensuring legal compliance and facilitating participation through online voting for minority shareholders[130]. - The board of directors convened 8 meetings, adhering to legal procedures and actively engaging in training to fulfill their responsibilities diligently[132]. - The supervisory board met 7 times, ensuring compliance and legality in the financial operations and management of the company[133]. - The company maintains a complete and independent asset structure, with no disputes over ownership or potential conflicts regarding asset rights[136]. - The company has established an independent financial department with a separate accounting system, ensuring financial decision-making autonomy[137]. - The governance structure of the company is increasingly refined, with no adverse effects from the controlling shareholder on its independence and operations[131]. - The company has not engaged in any related party transactions that could significantly impact its independence or fairness[137]. Employee Management and Compensation - The total number of employees at the end of the reporting period is 2,594, with 1,176 in the parent company and 1,418 in major subsidiaries[166]. - The professional composition includes 1,830 production personnel, 103 sales personnel, 331 technical personnel, 67 financial personnel, and 263 administrative personnel[166]. - The company has established a talent training mechanism, including onboarding, on-the-job, and transfer training programs[168]. - The company has implemented an employee stock incentive plan approved by the board and shareholders, aimed at motivating employees[173]. - The company emphasizes a performance-oriented compensation system to enhance employee efficiency and contributions[167]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to CNY 4.18 million[154]. Social Responsibility and Environmental Compliance - The company emphasizes social responsibility, actively participating in charitable activities such as donations to disability welfare foundations[188]. - The company has not reported any major environmental issues or administrative penalties related to environmental problems during the reporting period[187]. - Employee rights are prioritized, with a focus on creating a good working environment and providing career development opportunities[189]. Future Outlook - The company provided a positive outlook for 2024, projecting a revenue growth of 10-15%[148]. - New product launches are expected to contribute an additional 50 million RMB in revenue in the next quarter[148]. - Market expansion plans include entering two new international markets by Q3 2024[148].

厦门唯科模塑科技股份有限公司募集资金管理办法 厦门唯科模塑科技股份有限公司 募集资金管理办法 2024 年 5 月 1 厦门唯科模塑科技股份有限公司募集资金管理办法 募集资金管理办法 为规范厦门唯科模塑科技股份有限公司（以下简称"公司"）募集资金的管理 和使用，最大限度地保障投资者的利益，根据《中华人民共和国公司法》《中华 人民共和国证券法》以及深圳证券交易所（以下简称"深交所"）《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《公 司规范运作》）、《深圳证券交易所创业板股票上市规则》等有关法律法规和其他 规范性文件的要求，结合公司的实际情况，特制定本办法。 第一章 总 则 第一条 本办法所称募集资金是指公司通过发行股票及其衍生品种，向投资 者募集并用于特定用途的资金，但不包括上市公司实施股权激励计划募集的资金。 第二条 公司应当审慎使用募集资金，保证募集资金的使用与招股说明书或 者募集说明书的承诺相一致，不得随意改变募集资金的投向。公司应当真实、准 确、完整地披露募集资金的实际使用情况，并在年度审计的同时聘请会计师事务 所对募集资金存放与使用情况进行鉴证。 第三条 募集 ...